AstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial

FierceBiotechAstraZeneca scraps FLAP inhibitor after flunking phase 2 asthma trial

FierceBiotechRising costs push GE HealthCare to cut outlook as it restructures units and leadership

FierceBiotechTeva inks $700M Emalex buyout to bag near-approval Tourette drug

FierceBiotechAstraZeneca restarts £300M investment in UK, but Merck not budging

CellSpatial organization and detection of social odors in mouse primary olfactory system

CellUnbiased niche labeling maps immune-excluded niche in bone metastasis

CellA spatial code governs olfactory receptor choice and aligns sensory maps in the nose and brain

CellErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging

CellSensing endoplasmic reticulum redox state by ethylene receptors

BioPharma DiveChiesi to buy KalVista in $1.9B deal for rare disease drug

Endpoints NewsBristol Myers reaches a crossroads as a make-or-break year takes shape

Endpoints NewsPfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue